Drug intelligence / Profile preview

NOVO-111

Development stage: Preclinical
Lead developer: InnovoTEX
Modality: Small Molecules
Administration: Intravenous

Overview

NOVO-111 is a novel gadolinium(III) texaphyrin-platinum(IV) complex developed by Innovotex as a tumor-targeted prodrug of oxaliplatin. The molecule utilizes a texaphyrin macrocycle to enhance tumor localization and redox activity, aiming to improve the delivery of platinum(II) species to malignant tissues while minimizing systemic toxicity. Preclinical studies in colorectal cancer models (HCT-116) demonstrate that NOVO-111 achieves higher platinum accumulation in tumors and superior growth inhibition compared to oxaliplatin, with a favorable safety profile. It is being investigated for the treatment of colorectal and other solid tumors.

Other names: gadolinium(III) texaphyrin-platinum(IV) complex

Targets

DNA

Beyond the preview

Go deeper on NOVO-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVO-111.

Explore the full profile